Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of riliprubart in refractory chronic inflammatory demyelinating polyneuropathy
jRCT2031240109Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Riliprubart Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of participants experiencing a response, Percentage of participants randomized to riliprubart with lasting response and 1 more. Started May 2025; status: active, not recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2031240109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240109.